CG
NTLA icon

Cutler Group’s Intellia Therapeutics NTLA Stock Holding History

Cutler Group’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1,000
Closed -$13K – 4099
2023
Q3 		$13K Hold
1,000
– – ﹤0.01% 2327
2023
Q2 		$7K Buy
1,000
+900
+900% +$36.5K ﹤0.01% 2455
2023
Q1 		$6K Hold
100
– – ﹤0.01% 2649
2022
Q4 		$6K Sell
100
-10,800
-99% -$514K ﹤0.01% 3061
2022
Q3 		$227K Buy
10,900
+4,300
+65% +$267K 0.02% 906
2022
Q2 		$250K Hold
6,600
– – 0.02% 882
2022
Q1 		$177K Buy
6,600
+6,500
+6,500% +$551K 0.01% 1282
2021
Q4 		$3K Buy
+100
New +$12.5K ﹤0.01% 4551
2021
Q3 		– Sell
-17,100
Closed -$69K – 6155
2021
Q2 		$69K Buy
+17,100
New +$1.33M ﹤0.01% 2208
2018
Q2 		– Sell
-2,300
Closed -$19K – 4652
2018
Q1 		$19K Buy
2,300
+1,100
+92% +$27.1K ﹤0.01% 2335
2017
Q4 		$6K Sell
1,200
-21,300
-95% -$492K ﹤0.01% 3502
2017
Q3 		$24K Buy
+22,500
New +$424K ﹤0.01% 2961

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Cutler Group's NTLA Position: Q1 2024 in Review

Cutler Group sold out of Intellia Therapeutics (NTLA) in Q1 2024, closing a stake of 200 shares — an estimated $6K sold.

Cutler Group first reported a position in NTLA in Q2 2017 and held it in 16 quarters. The position peaked at $1.49M in Q2 2021. 284 funds tracked by Wall St. Rank hold NTLA as of Q1 2024.

  • Cutler Group reported no remaining Intellia Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Cutler Group sold 200 Intellia Therapeutics shares in Q1 2024, an estimated $6K.
  • Cutler Group first reported a position in Intellia Therapeutics in Q2 2017 and held it in 16 quarters.
  • Cutler Group's Intellia Therapeutics position peaked at $1.49M in Q2 2021.
  • 284 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.